XRTX Stock Overview
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
+ 1 more risk
Notes are coming soon
XORTX Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.78|
|52 Week High||CA$3.00|
|52 Week Low||CA$0.78|
|1 Month Change||-30.36%|
|3 Month Change||-30.36%|
|1 Year Change||-64.71%|
|3 Year Change||-52.54%|
|5 Year Change||-80.74%|
|Change since IPO||-86.71%|
Recent News & Updates
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn SituationAug 23
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its BusinessApr 01
We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To GrowDec 16
Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In GrowthSep 01
|XRTX||CA Pharmaceuticals||CA Market|
Return vs Industry: XRTX underperformed the Canadian Pharmaceuticals industry which returned -59.1% over the past year.
Return vs Market: XRTX underperformed the Canadian Market which returned -0.6% over the past year.
|XRTX Average Weekly Movement||16.2%|
|Pharmaceuticals Industry Average Movement||14.2%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||19.1%|
|10% least volatile stocks in CA Market||3.9%|
Stable Share Price: XRTX is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: XRTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
XORTX Therapeutics Inc. Fundamentals Summary
|XRTX fundamental statistics|
Is XRTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XRTX income statement (TTM)|
|Cost of Revenue||CA$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.18|
|Net Profit Margin||0.00%|
How did XRTX perform over the long term?See historical performance and comparison